Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Japanese Pharma Exercises Option Under 2017 Deal
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
